Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study.

van der Aart-van der Beek AB, Apperloo E, Jongs N, Rouw DB, Sjöström CD, Friedli I, Johansson L, van Raalte DH, Hoogenberg K, Heerspink HJL

Diabetes, obesity & metabolism13 Mar 2023Cited by 28 (Europe PMC)

PMID36843215DOI10.1111/dom.15033PepBankPUB-36843215

Publisher page PubMedAsk about this study

Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study16

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, mean UACR change from baseline during exenatide was -7.7% (95% CI -23.5% to 11.2%).
In plain wordsIn patients with type 2 diabetes and albuminuria, urine albumin fell 7.7% on average from baseline with exenatide, but the range included no change.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseUACR change
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Studied dose
2 mg/wk · 6 weeksAs given in this study (human).
Measurements
UACR change
−7.7%
Exenatide
Source sentences
Summary
Mean percentage change in UACR from baseline was -21.9% (95% CI: -34.8% to -6.4%) during dapagliflozin versus -7.7% (95% CI: -23.5% to 11.2%) during exenatide and -26.0% (95% CI: -38.4% to -11.0%) during dapagliflozin-exenatide treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
Report a problemFND-3684321501
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide numerically reduced systolic pressure more than dapagliflozin alone.
In plain wordsIn patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide numerically reduced systolic blood pressure more than dapagliflozin alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSystolic blood pressure versus dapagliflozin
Study
n: not reported in source
Comparator
Dapagliflozin alone
Outcome group
Blood pressure · Cardiovascular
Studied dose
2 mg/wk · 6 weeksAs given in this study (human).
Source sentences
Summary
Numerically greater reductions in systolic blood pressure, body weight and eGFR were observed during dapagliflozin-exenatide treatment compared with dapagliflozin or exenatide alone.
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
Report a problemFND-3684321504
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide numerically reduced weight more than dapagliflozin alone.
In plain wordsIn patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide numerically reduced weight more than dapagliflozin alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight versus dapagliflozin
Study
n: not reported in source
Comparator
Dapagliflozin alone
Outcome group
Body weight · Metabolic and weight
Studied dose
2 mg/wk · 6 weeksAs given in this study (human).
Source sentences
Summary
Numerically greater reductions in systolic blood pressure, body weight and eGFR were observed during dapagliflozin-exenatide treatment compared with dapagliflozin or exenatide alone.
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
Report a problemFND-3684321506
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide numerically reduced eGFR more than dapagliflozin alone.
In plain wordsIn patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide numerically reduced estimated kidney filtration more than dapagliflozin alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseeGFR versus dapagliflozin
Study
n: not reported in source
Comparator
Dapagliflozin alone
Outcome group
Kidney function · Kidney and urinary
Studied dose
2 mg/wk · 6 weeksAs given in this study (human).
Source sentences
Summary
Numerically greater reductions in systolic blood pressure, body weight and eGFR were observed during dapagliflozin-exenatide treatment compared with dapagliflozin or exenatide alone.
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
Report a problemFND-3684321508
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, renal blood flow did not significantly change during exenatide treatment.
In plain wordsIn patients with type 2 diabetes and albuminuria, kidney blood flow did not significantly change with exenatide compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeRenal blood flow
Study
n: not reported in source
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
2 mg/wk · 6 weeksAs given in this study (human).
Source sentences
Summary
Renal blood flow and effective renal plasma flow (ERPF) did not significantly change with either treatment regimen.
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
Report a problemFND-3684321510
06HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, ERPF did not significantly change during exenatide treatment.
In plain wordsIn patients with type 2 diabetes and albuminuria, kidney plasma flow did not significantly change with exenatide compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeEffective renal plasma flow
Study
n: not reported in source
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
2 mg/wk · 6 weeksAs given in this study (human).
Source sentences
Summary
Renal blood flow and effective renal plasma flow (ERPF) did not significantly change with either treatment regimen.
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
Report a problemFND-3684321512
07HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, filtration fraction did not change during exenatide treatment.
In plain wordsIn patients with type 2 diabetes and albuminuria, kidney filtration fraction did not change with exenatide compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeFiltration fraction
Study
n: not reported in source
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
2 mg/wk · 6 weeksAs given in this study (human).
Source sentences
Summary
The filtration fraction did not change during treatment with dapagliflozin or exenatide, and decreased during dapagliflozin-exenatide treatment (-1.6% [95% CI: -3.2% to -0.01%]; P = .048).
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
Report a problemFND-3684321515

Studies that did not test the peptide alone9

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

08HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide reduced UACR from baseline.
In plain wordsIn patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide reduced urine albumin compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseUACR change with combination
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Measurements
UACR change
−26%
Dapagliflozin-exenatide
Source sentences
Summary
Mean percentage change in UACR from baseline was -21.9% (95% CI: -34.8% to -6.4%) during dapagliflozin versus -7.7% (95% CI: -23.5% to 11.2%) during exenatide and -26.0% (95% CI: -38.4% to -11.0%) during dapagliflozin-exenatide treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3684321502
09HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther
In patients with type 2 diabetes and albuminuria, albuminuria responses to exenatide and the other treatments did not correlate.
In plain wordsIn patients with type 2 diabetes and albuminuria, urine albumin responses to exenatide and other treatments did not correlate.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeCorrelation of albuminuria responses
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
No correlation was observed in albuminuria responses between the different treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3684321503
10HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide numerically reduced systolic pressure more than exenatide alone.
In plain wordsIn patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide numerically reduced systolic blood pressure more than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSystolic blood pressure versus exenatide
Study
n: not reported in source
Comparator
Exenatide alone
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
Numerically greater reductions in systolic blood pressure, body weight and eGFR were observed during dapagliflozin-exenatide treatment compared with dapagliflozin or exenatide alone.
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3684321505
11HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide numerically reduced weight more than exenatide alone.
In plain wordsIn patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide numerically reduced weight more than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight versus exenatide
Study
n: not reported in source
Comparator
Exenatide alone
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Numerically greater reductions in systolic blood pressure, body weight and eGFR were observed during dapagliflozin-exenatide treatment compared with dapagliflozin or exenatide alone.
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3684321507
12HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide numerically reduced eGFR more than exenatide alone.
In plain wordsIn patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide numerically reduced estimated kidney filtration more than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseeGFR versus exenatide
Study
n: not reported in source
Comparator
Exenatide alone
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Numerically greater reductions in systolic blood pressure, body weight and eGFR were observed during dapagliflozin-exenatide treatment compared with dapagliflozin or exenatide alone.
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3684321509
13HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, renal blood flow did not significantly change during dapagliflozin-exenatide treatment.
In plain wordsIn patients with type 2 diabetes and albuminuria, kidney blood flow did not significantly change with dapagliflozin-exenatide compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeRenal blood flow with combination
Study
n: not reported in source
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Renal blood flow and effective renal plasma flow (ERPF) did not significantly change with either treatment regimen.
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3684321511
14HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, ERPF did not significantly change during dapagliflozin-exenatide treatment.
In plain wordsIn patients with type 2 diabetes and albuminuria, kidney plasma flow did not significantly change with dapagliflozin-exenatide compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeEffective renal plasma flow with combination
Study
n: not reported in source
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Renal blood flow and effective renal plasma flow (ERPF) did not significantly change with either treatment regimen.
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3684321513
15HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, all but two patients receiving dapagliflozin-exenatide showed ERPF reductions.
In plain wordsIn patients with type 2 diabetes and albuminuria, all but two receiving dapagliflozin-exenatide showed lower kidney plasma flow than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseParticipants with reduced ERPF on combination
Study
n: not reported in source
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Measurements
Patients without ERPF reduction
2 patients
Dapagliflozin-exenatide
Source sentences
Summary
However, all but four and two patients in the dapagliflozin and dapagliflozin-exenatide groups, respectively, showed reductions in ERPF.
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3684321514
16HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide decreased filtration fraction from baseline.
In plain wordsIn patients with type 2 diabetes and albuminuria, dapagliflozin-exenatide decreased kidney filtration fraction compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFiltration fraction with combination
Study
n: not reported in source
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Measurements
Filtration fraction change
−1.6%
Dapagliflozin-exenatide
Source sentences
Summary
The filtration fraction did not change during treatment with dapagliflozin or exenatide, and decreased during dapagliflozin-exenatide treatment (-1.6% [95% CI: -3.2% to -0.01%]; P = .048).
1 context sentence(design, population, supporting numbers)
Summary · context
completed three 6-week treatment periods, during which dapagliflozin 10 mg/d, exenatide 2 mg/wk and both drugs combined were given in random order.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3684321516

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.